EUVIMEDEUVIMED entdecken
Übersichtsarbeit

RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy

Jingsheng Cai, Shaoyi Chen, Zheng Liu, Haoran Li, Peiyu Wang, Fan Yang, Yun Li, Kezhong Chen, Ming Sun iD, Mantang Qiu iD

Immunology · 2024-12 · 173 (4) · 634-653

DOI: 10.1111/imm.13861 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 28.09.2024. Verfasst von Jingsheng Cai und 9 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunotherapy, Adoptive, SARS-CoV-2. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 181 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Nova Program, Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The remarkable success of mRNA‐based coronavirus 2019 (COVID‐19) vaccines has propelled the advancement of nanomedicine, specifically in the realm of RNA technology and nanomaterial delivery systems. Notably, significant strides have been made in the development of RNA‐based in vivo chimeric antigen receptor (CAR) therapy. In comparison to the conventional ex vivo CAR therapy, in vivo CAR therapy offers several benefits including simplified preparation, reduced costs, broad applicability and decreased potential for carcinogenic effects. This review summarises the RNA‐based CAR constructs in in vivo CAR therapy, discusses the current applications of in vivo delivery vectors and outlines the immune cells edited with CAR molecules. We aim for the conveyed messages to contribute towards the advancement of in vivo CAR application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenImmunotherapy, AdoptiveSARS-CoV-2HumansCOVID-19AnimalsCOVID-19 VaccinesNeoplasmsNanomedicineNanoparticles

Stichwörter der Autor:innen

RNAin vivo CAR therapynanocarriers

Substanzen

Receptors, Chimeric AntigenCOVID-19 Vaccines

Autor:innen und Institutionen

  • Thoracic Oncology Institute, Peking University People's Hospital, Beijing, People's Republic of China.
  • Department of Thoracic Surgery, Peking University People's Hospital, Beijing, People's Republic of China.
  • Institute of Advanced Clinical Medicine, Peking University, Beijing, People's Republic of China.
  • Department of Oncology Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, People's Republic of China.

ORCID-Profile: Ming Sun, Mantang Qiu

Förderung

  • National Natural Science Foundation of China
  • Beijing Nova Program
  • Research Unit of Intelligence Diagnosis and Treatment in Early Non-small Cell Lung Cancer
  • National Key R&D Program of China
  • National Key Research and Development Program of China

Zitieren

APA

Cai, J., Chen, S., Liu, Z., Li, H., Wang, P., Yang, F., Li, Y., Chen, K., Sun, M., & Qiu, M. (2024). RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy. Immunology, 173(4), 634-653. https://doi.org/10.1111/imm.13861

Vancouver

Cai J, Chen S, Liu Z, Li H, Wang P, Yang F, et al. RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy. Immunology. 2024;173(4):634-653. doi:10.1111/imm.13861

BibTeX
@article{Cai2024,
  author = {Cai, Jingsheng and Chen, Shaoyi and Liu, Zheng and Li, Haoran and Wang, Peiyu and Yang, Fan and Li, Yun and Chen, Kezhong and Sun, Ming and Qiu, Mantang},
  title = {RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy},
  journal = {Immunology},
  year = {2024},
  volume = {173},
  number = {4},
  pages = {634--653},
  doi = {10.1111/imm.13861}
}
Kostenlos starten →